AVBP (ArriVent BioPharma) Accumulated Depreciation : $0.00 Mil (As of Sep. 2024)

View and export this data going back to 2024. Start your Free Trial

What is ArriVent BioPharma Accumulated Depreciation?

Note: A negative number here means the assets are depreciated. When depricates more, the absolute value gets bigger.

ArriVent BioPharma Accumulated Depreciation Historical Data

The historical data trend for ArriVent BioPharma's Accumulated Depreciation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ArriVent BioPharma Accumulated Depreciation Chart

ArriVent BioPharma Annual Data

Trend

Dec21

Dec22

Dec23

Accumulated Depreciation

ArriVent BioPharma Quarterly Data
	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Accumulated Depreciation	Get a 7-Day Free Trial						-	-	-	-	-

ArriVent BioPharma Accumulated Depreciation Calculation

The cumulative depreciation of an asset up to a single point in its life. Regardless of the method used to calculate it, the depreciation of an asset during a single period is added to the previous period's accumulated depreciation to get the current accumulated depreciation.

ArriVent BioPharma Accumulated Depreciation Related Terms

Thank you for viewing the detailed overview of ArriVent BioPharma's Accumulated Depreciation provided by GuruFocus.com. Please click on the following links to see related term pages.

ArriVent BioPharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ArriVent BioPharma Inc (NAS:AVBP) » Definitions » Accumulated Depreciation

Comparable Companies

Traded in Other Exchanges

N/A

Address

18 Campus Boulevard, Suite 100, Newtown Square, Philadelphia, PA, USA, 19073

Website

https://arrivent.com

ArriVent BioPharma Inc is a clinical stage biopharmaceutical company dedicated to the identification, development and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize team's deep drug development experience to maximize the potential of lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.